Cabaletta Bio (CABA)
(Delayed Data from NSDQ)
$7.86 USD
+0.05 (0.64%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $7.85 -0.01 (-0.13%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Cabaletta Bio, Inc. [CABA]
Reports for Purchase
Showing records 21 - 40 ( 43 total )
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
Addition of CD19-targeting CAR-T Broadens Cabaletta''s Pipeline in Autoimmune Disease
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
Pulling Levers to Win; Management Implements Dosing Changes to Accelerate Clinical Results
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
Nevertheless, DSG3-CAART Persisted; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
A Busy Week as We Learn More About DSG3 Program; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
4Q21 Update: DesCAARTes Progressing and MuSK Trial to Kick Off This Year; Reiterate Buy; PT Down to $11
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
Rx for Portfolios, Part 1: Companies With Transformative Clinical Readouts Fast Approaching
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
An Early Win Would?ve Been Nice, But We Urge Patience as Plenty of Efficacy-Enhancing Levers Remain
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
DesCAARTes Progressing Without Any Safety Events as First Efficacy Data Expected This Quarter; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
No Meaningful Acute Safety Issues in Second DesCAARTes Cohort; Initial Activity Data Expected 4Q; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
Acute First-in-Human Safety Seen in DesCAARTes Cohort 1 and New Indication Announced on 1Q Call; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
Positive First-In-Human Acute Safety in PV and New Indication Announced, Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
No News Is Good News as DesCAARTes Continues Dosing; Reiterate Buy, Price Target to $22
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
Takeaways From Our Coverage at the 2021 H.C. Wainwright BioConnect Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
Biotech Should Keep the Wind at its Back in 2021; Top Healthcare Picks
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department